Sensitization of tumors to chemotherapy through gene therapy

Advances in Experimental Medicine and Biology

Volumn 465, Issue , 2000, Pages 273-291

  Gjerset, R A ^a   Mercola, D ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

ADENOVIRUS; CANCER CHEMOTHERAPY; CANCER INHIBITION; DNA DAMAGE; DRUG SENSITIZATION; GAMMA RADIATION; GENE THERAPY; GENE TRANSFER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE; VIRUS GENE; VIRUS RECOMBINANT;

ANIMALS; DNA DAMAGE; DRUG THERAPY; GENE THERAPY; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE;

EID: 0034475171     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (51)

1. Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors
2. p53 binds single stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain
3. DNA repair mechanisms associated with cellular resistance to antitumor drugs: Potential novel targets
4. Ha-ras augments c-Jun activity and stimulates phosphorylation of its activation domain
5. Induction of c-los expression through JNK-mediated TCF/EIkphosphorylation
6. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67)
7. Thymocyte apoptosis induced by p53-dependent and independent pathways
8. Therapeutic applications of oligonucleotides
9. Molecular mechanisms of antisense drugs: Rnase H
10. Cisplatin resistance and DNA repair
11. Antisense oligonucleotides as inhibitors of signal transduction: Development from research tools to therapeutic agents
12. cAMP and tumor necrosis factor competitively regulated transcriptional activation through a nuclear factor binding to the cAMPresponsive element/activating transcription fact element of the endothelial leukocyte adhesion molecule-1 (E-selectin) promoter
13. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
14. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function
15. The role of DNA mismatch repair in drug resistance
16. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
17. The utility of an antifos ribozyme in reversing cisplatin resistance in human carcinomas
18. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53
19. Tumor regression in vivo following p53 combination therapy
20. Platinum-DNA adduct, nucelotide excision repair and platinum based anti-cancer chemotherapy
21. Transcription factor ATF2 regulation by the INK signal transduction pathway
22. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain
23. A polymerase chain reaction-based method to detect cisplatin adducts in specific genes
24. p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches
25. The tumor suppressor genes
26. p53, the cellular gatekeeper for growth and division
27. ATF-2 contains a phosphorylation-dependent transcriptional activation domain
28. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents
29. p53-mediated apoptosis modulates the cytotoxicity of anti-cancer agents
30. p53 status and the efficacy of cancer therapy in vivo
31. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression
32. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer
33. Interaction of nuclear proteins with an AP1/CRE-like promoter sequence in the human TNF-alpha gene
34. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer
35. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
36. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and cor-relations with the growth-inhibitory potency of 123 anticancer agents
37. Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines
38. The JNK/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin
39. Inhibition of the JNK pathway blocks cell cycle progression in human tumor cells
40. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
41. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
42. Mechanisms of resistance to xenobiotics in human therapy
43. Elevated expression of thymidylate synthase cycle genes in cisplatinresistant human ovarian carcinoma A2780 cells
44. Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients
45. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein
46. Oncogenic and transcriptional cooperation with Ha-ras requires phosphorylation of c-Jun on serines 63 and 73
47. Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73
48. Regulation and mechanisms of mammalian gene amplification
49. Problems in interpretation of data derived from in vitro and in vivo use of antisence oligodeoxynucleotides
50. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents
51. Both ATP-2 and c-Jun are phosphorylated by stress-activated protein kinases in response to UV irradiation